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Abstract
Background: Despite the extraordinary scale up of HIV prevention, care and treatment services in sub-Saharan
Africa (SSA) over the past decade, the overall effectiveness of HIV programs has been significantly hindered by high
levels of attrition across the HIV care continuum. Data from “real-life” settings are needed on the effectiveness of an
easy to deliver package of services that can improve overall performance of the HIV care continuum.
Methods/Design: We are conducting an implementation science study using a two-arm cluster site-randomized
design to determine the effectiveness of a combination intervention strategy (CIS) using feasible, evidence-based,
and practical interventions—including (1) point-of-care (POC) CD4 count testing, (2) accelerated antiretroviral
therapy initiation for eligible individuals, and (3) SMS reminders for linkage to and retention in care—as compared
to the standard of care (SOC) in Mozambique in improving linkage and retention among adults following HIV
diagnosis. A pre-post intervention two-sample design is nested within the CIS arm to assess the incremental
effectiveness of the CIS plus financial incentives (CIS + FI) compared to the CIS without FI on study outcomes.
Randomization is done at the level of the study site, defined as a primary health facility. Five sites are included from
the City of Maputo and five from Inhambane Province. Target enrollment is a total of 2,250 adults: 750 in the SOC
arm, 750 in the CIS cohort of the intervention arm and 750 in the CIS + FI cohort of the intervention arm (average
of 150 participants per site). Participants are followed for 12 months from time of HIV testing to ascertain a
combined endpoint of linkage to care within 1 month after testing and retention in care 12 months from HIV test.
Cost-effectiveness analyses of CIS compared to SOC and CIS + FI compared to CIS will also be conducted.
Discussion: Study findings will provide evidence on the effectiveness of a CIS and the incremental effectiveness of
a CIS + FI in a “real-life” service delivery system in a SSA country severely impacted by HIV.
Trial registration: Clinicaltrials.gov, NCT01930084
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Background
Although the extraordinary scale-up of HIV testing, care,
and treatment programs in sub-Saharan Africa (SSA) has
led to more than eight million persons initiating antiretro-
viral therapy (ART), the overall effectiveness of HIV pro-
grams has been significantly hindered by high levels of
attrition across the HIV care continuum in the region
[1-4]. Linkage to HIV care is the first step in the HIV care
continuum and is essential for assessing the health of pa-
tients, determining ART eligibility and promptly initiating
ART among eligible patients (Figure 1) [5]. Systematic re-
views of studies in SSA indicate that on average 59-78% of
adults testing HIV positive link to care within three months
of diagnosis, as determined by receipt of a CD4 count as-
sessment [3,6]. Retention in care, another critical step in
the HIV care continuum, is required for prevention and
treatment of opportunistic infections, continued clinical
and laboratory monitoring for ART eligibility among those
not eligible upon enrollment in care, timely ART initiation,
and follow-up and provision of supportive care [7-14].
However, recent reviews from SSA estimate that only 45%
of patients not yet eligible to initiate ART are retained in
pre-ART care, only 66% of eligible individuals initiate ART,
and of those initiating, only 65% are retained after three
years [6,15]. Ultimately, less than one-third of individuals
testing HIV positive in SSA are believed to have linked to
and engaged in care 12 months after diagnosis [8,9].
Interventions to improve linkage to and retention in
care can target structural, biomedical, and/or behav-
ioral barriers reported by patients [5]. Reported struc-
tural barriers include the multiple visits required for
counseling and ART eligibility determination; transport
costs and distances; and financial, work, and childcare
constraints [16-21]. Interventions addressing these bar-
riers include point of care (POC) CD4 count testing
immediately following diagnosis to consolidate labora-
tory testing to determine ART eligibility at the time of
HIV testing, and financial incentives (FI) to offset the
financial costs incurred through lost wages, transport, and
other costs of care [22-25]. Biomedical barriers include de-
layed ART initiation among eligible patients, which may
be remediated through accelerated or ‘fast-track’ ART ini-
tiation. Behavioral barriers include patients forgetting ap-
pointments and lack of understanding of HIV disease and
associated care, including the need for care while healthy,
which can be addressed through appointment reminders.
Mozambique, a country in Southern Africa severely af-
fected by the HIV epidemic, has an HIV prevalence of
11.5% [26] and an estimated 1.7 million people living with
HIV (PLWH) [27]. The Government of Mozambique has
made considerable efforts to strengthen its health system
to address the HIV epidemic such that by December 2012,
more than 500,000 patients were enrolled in HIV care and
treatment services, and 300,000 PLWH had initiated ART
[28]. Despite these achievements, several important chal-
lenges remain in ensuring high quality care across the
HIV care continuum in Mozambique. First, linkage to care
following HIV diagnosis in Mozambique is believed to be
very low with the limited available data indicating that
only 57% of adults newly diagnosed with HIV enroll in
care within 30 days after diagnosis [29]. Further, for indi-
viduals who do enroll in HIV care, retention is among the
lowest in SSA, with recent data indicating that less than
50% of patients not yet eligible for ART remain in care at
12 months and less than 50% of patients on ART are
retained 12 months later [29-33].
In order to address these challenges, we are conduct-
ing an implementation science study assessing the
effectiveness and cost-effectiveness of a combination
intervention strategy (CIS) comprised of several feas-
ible, evidence-based and practical interventions on a
combined outcome of linkage to and retention in com-
prehensive care among adults newly testing HIV posi-
tive in Mozambique.
Figure 1 The HIV care continuum [5].
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Primary objective
The primary objective is to evaluate the effectiveness of
CIS compared to SOC, and of CIS with the addition of fi-
nancial incentives (CIS + FI) compared to CIS, on the com-
bined outcome of linkage to HIV care within 1 month and
retention in care at 12 months at the same health facility of
diagnosis among adults newly testing HIV positive.
Secondary objectives
The secondary objectives include to: 1) evaluate the effect-
iveness of CIS compared to SOC and the incremental ef-
fectiveness of CIS + FI compared to CIS in distinct steps
along the HIV care continuum, including linkage to HIV
care within 12 months from positive HIV test, retention in
care at 12 months from positive HIV test, time from ART
eligibility to ART initiation, and disease progression (new
World Health Organization [WHO] stage III/IV event,
hospitalization, CD4 count, death); 2) evaluate the cost-
effectiveness of CIS compared to SOC and the incremental
cost-effectiveness of CIS + FI compared to CIS; and 3)
assess feasibility and participant acceptability of the
relative benefit of the interventions included in CIS and
CIS + FI in enhancing linkage and retention.
Methods
Study design
The study uses a two-arm cluster site-randomized de-
sign. Additionally, a pre-post intervention two-sample
design is nested within the intervention arm to assess
the incremental effectiveness of CIS + FI compared to
CIS without FI on study outcomes. One cohort of partic-
ipants (cohort 1) is enrolled in the SOC arm and two co-
horts (cohorts 2 and 3) are enrolled sequentially in the
intervention arm (Figure 2). Cohort 2 receives CIS con-
sisting of POC CD4 count testing at time of HIV testing,
accelerated ART initiation, and cellular appointment re-
minders and is enrolled concurrently to cohort 1 in the
SOC arm; outcomes among cohort 2 will be compared to
those among cohort 1. Cohort 3 receives CIS + FI, consist-
ing of CIS plus FI at key points in the HIV care continuum
and is enrolled following enrollment of all participants in
cohort 2 in the CIS arm; outcomes among cohort 3 will be
compared to those among cohort 2.
Study sites and participants
The study site is defined as a primary health facility provid-
ing both HIV testing and HIV care and treatment services.
Within a given health facility, all HIV testing and counsel-
ing (HCT) points are included with the exception of pre-
vention of mother-to-child transmission (PMTCT) and
Tuberculosis (TB) clinic points of testing, as these testing
points follow different linkage to care procedures. Primary
health facilities were chosen as study sites, rather than lar-
ger provincial hospitals, as they reflect the decentralized
HIV care system in Mozambique in which HIV services
are provided in an outpatient clinic setting. A total of
10 sites were selected from the 66 health facilities in the
region based on existing data suggesting they had suffi-
cient numbers of patients testing HIV positive and en-
rolling in HIV care to meet the study sample size needs
(see below) (Table 1). Sites are randomized to the SOC
arm or the intervention arm using matched-pair
randomization with matching done by facility location
(rural, peri-urban, or urban) and expected number of
adults enrolling in HIV care at each facility per month.
The target study population includes 2,250 treatment-
naïve adults who newly test HIV positive at study sites:
750 in the SOC arm (cohort 1), 750 in the CIS cohort of
the intervention arm (cohort 2) and 750 in the CIS + FI
cohort of the intervention arm (cohort 3), with an average
of 150 participants per site. Study participants must be
18 years of age or older, test positive at the participating
HCT point within the health facility with written proof of
test result, agree to be referred to HIV care services within
Figure 2 Overview of study design.
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the health facility, agree to provide contact information,
agree to adhere to study procedures and be able to provide
informed consent. Study participants without access to
cellular phones and those who are illiterate are included.
Those without access to cellular phones enrolled at inter-
vention sites are unable to receive the SMS component of
the intervention; this information is tracked by the study
staff. Exclusion criteria include being pregnant at the time
of study enrollment, planning to leave the community in
the next 12 months, having enrolled in HIV care in the
past six months at any health facility, having initiated ART
(for any duration) in the past six months at any health fa-
cility, currently taking ART, or being unable to speak or
understand Portuguese or Xitsua.
Participants are recruited and enrolled immediately fol-
lowing HIV diagnosis at the sites. After patients receive a
positive HIV test result, post-test counseling, and in the
case of intervention sites, POC CD4 count testing and
pre-ART counseling if eligible for ART, clinic staff informs
them about the study and directs those interested in
participating to study staff for more information. Study
staff further explains the study and if the patient is inter-
ested, screens them for eligibility and completes the in-
formed consent process.
Study interventions
Standard of Care (SOC)
At sites randomized to the SOC arm, patients are managed
per current Mozambican Ministry of Health (MOH) guide-
lines (Table 2). HCT counselors refer patients diagnosed
with HIV to attend HIV care services at their preferred
health facility as soon as possible. In most cases, patients
are verbally referred to the on-site HIV care and treatment
clinic. Patients who present to the health facility reception-
ist to enroll in HIV care are scheduled for an appointment
for clinical consultation in the on-site HIV clinic. Following
the clinical consultation, patients are sent to the health
facility laboratory to have blood drawn for CD4 count test-
ing and baseline laboratory tests. Laboratory tests are proc-
essed at the health facility laboratory in four of the five
Table 1 Study sites, randomization assignments, and HIV counseling and testing points
Matched pair Province Facility Randomization
assignment
Urban/Rural locale HIV testing point for
study enrollment
Number of enrollees in
HIV care
1 Maputo City Bagamoio CIS Urban VCT >170 per month
Maputo City Mavalane SOC Urban PICT* >170 per month
2 Inhambane Urbano CIS Urban VCT < 170 per month
Inhambane Maxixe SOC Urban VCT < 170 per month
3 Maputo City Jose Macamo SOC Peri-urban VCT >170 per month
Maputo City Zimpeto CIS Peri-urban VCT >170 per month
4 Inhambane Massinga SOC Peri-urban VCT < 170 per month
Inhambane Chicuque CIS Peri-urban VCT < 170 per month
5 Inhambane Morrumbene SOC Rural PICT** < 170 per month
Inhambane Zavala CIS Rural VCT < 170 per month
*Mavalane = Psychosocial services testing point; **Morrumbene = Triage testing point.
Table 2 Combination intervention strategy interventions compared to standard of care
Intervention Standard of care CIS (CIS, CIS + FI) Barriers targeted
by interventions
CD4 testing CD4 (Cyflow, FACS Caliber/Count, POC CD4) at
HIV care site laboratory if linkage completed.
POC CD4 assays at HIV testing points. Structural
Turnaround time: 1–4 weeks. Turnaround time: immediate.
Accelerated ART initiation Within 1–2 months from linkage. Accelerated ART initiation within 1 week
from testing.
Biomedical
2-3 counseling sessions, all in HIV care. 2 counseling sessions, one in HCT
immediately following POC CD4 test
and one in HIV care.
Baseline laboratory tests results obtained prior
to initiation.
Draw blood for baseline laboratory tests,
and initiate prior to results.
Cellular appointment
reminders
None. SMS appointment reminders for all
participants.
Behavioral
Non-cash financial incentives None. Pre-paid cellular air time cards. Structural
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SOC sites, and are sent off-site for processing at the
remaining SOC site. Patients are asked to return for an-
other clinical consultation approximately one to two weeks
later to review laboratory results, at which point ART eligi-
bility is determined by CD4 count and WHO stage follow-
ing national guidelines: CD4 count ≤350 cells/μL and/or
WHO stage III/IV. Those who are ART eligible receive on
average three counseling sessions before initiating treat-
ment. Patients receiving ARTare requested to return to the
health facility every two weeks for the first month, at two
months, at six months, and then every six months there-
after. Patients not eligible for ART are requested to return
in six months for clinical evaluation and routine laboratory
testing. Peer educators follow-up with patients who miss
appointments on ad hoc basis via phone or home visits.
Combination Intervention Strategy (CIS)
In order to most closely approximate “real-life” service de-
livery, the clinical interventions of the CIS package (i.e.
POC CD4 count testing and accelerated ART initiation)
are provided by clinic staff to all patients receiving care at
the facility, not solely study participants. Study personnel
provide SMS appointment reminders and, for participants
in the CIS + FI cohort, FI only to study participants. Each
of these interventions is described below.
POC CD4 count testing
Patients at the intervention sites receive a POC CD4
count test in the HCT point of service immediately fol-
lowing HIV diagnosis by the HCT counselor. Results are
available and provided to the patient along with an ex-
planation of their meaning within 20 minutes. All pa-
tients, regardless of CD4 count, are provided with a
referral slip for the on-site HIV care clinic and instructed
to enroll in care as soon as possible, although particular
emphasis on prompt enrollment is provided to patients
who are ART eligible as described below. Patients not
yet eligible for ART who agree to enroll in HIV care im-
mediately are escorted to the receptionist’s office,
whereas those who are ART eligible receive the acceler-
ated ART initiation intervention described below.
Accelerated ART initiation for eligible patients
Patients with CD4 count ≤350 cells/μL as measured by
POC CD4 count testing receive referral for accelerated
ART initiation. Immediately following the POC CD4 count
measurement, the HCT counselor provides the first pre-
ART counseling session, in contra-distinction to the SOC
arm where it is provided only after the patient links to care
and receives a clinical consultation. Following the counsel-
ing session, the counselor escorts the patient to the recep-
tionist’s office for immediate enrollment in HIV care and
prompt ART initiation. The receptionist expedites sched-
uling of ART-eligible patients for a clinical consultation so
that it is scheduled as soon as possible, ideally on the same
day. Patients proceed immediately to have baseline labora-
tory tests drawn. At the clinical consultation, the clinician
evaluates the patient for ART initiation, and refers the pa-
tient for additional pre-ART counseling if necessary. Med-
ically eligible patients are initiated on ART on the same
day as their clinical consultation and prior to receipt of la-
boratory results.
Cellular appointment reminders
During the first month following study enrollment, study
participants receive weekly reminders via text messages to
link to care (“Hi. Your health is the most important thing.
Please remember to come to the health center for health
services”). For the remaining 11 months of their enroll-
ment in the study, participants receive monthly reminder
messages to remain engaged in care (“Hi. Continue coming
to the health center to take care of your and your family’s
health”). In addition, participants who successfully link to
HIV care receive appointment reminders tailored to their
upcoming appointments (“Hi. Your health is the most im-
portant thing. We expect to see you at your upcoming ap-
pointment scheduled for the day X”). In order to maintain
participant confidentiality, cellular appointment reminders
do not refer to HIV, HIV care services, a specific health fa-
cility, or reveal any personal information. Participants are
not asked to confirm receipt or reply to any messages.
Non-cash financial incentives
Participants in the CIS + FI cohort receive CIS interven-
tions plus a series of non-cash FI in the form of pre-paid
cellular air time cards. The non-cash FI air-time cards are
valued at approximately $5 USD and are provided upon the
following achievements: linkage into care within 1 month
of testing, and engagement in care by visiting the health fa-
cility for HIV care and treatment services at six months
and 12 months following study enrollment, for a total of
$15 USD over the study period.
Data collection
Data collection consists of participant interviews, extrac-
tion of patient-level data from medical records, and site
assessments.
Participant interviews
Participant interviews are conducted at baseline, and
one month and 12 months after study enrollment by
study staff using closed-ended questionnaires. The base-
line questionnaire collects information on patient socio-
demographics, travel to and time spent at the HIV clinic,
and HIV testing history. The 1-month and 12-month
questionnaires collect information on linkage to care
and retention in care. All three questionnaires collect in-
formation on quality of life and social support, perceived
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and experienced HIV stigma, and HIV knowledge and be-
liefs. Additionally, for patients in the intervention arm, the
follow-up interviews assess patient receipt and acceptabil-
ity of each intervention component. Baseline interviews
are completed at the health facility following receipt of
informed consent and contact information for follow-up
interviews. For the 1-month and 12-month follow-up in-
terviews, study staff makes up to four attempts to reach
the participant by phone to complete the interview. If the
participant cannot be reached by phone, study staff con-
ducts home visits in an attempt to locate the participant
and conduct the interviews. Additionally, participants who
are reached by phone and indicate a preference to return
to the health facility to complete the interview may do so.
Extraction of patient-level data from medical records
Upon study completion, clinical and immunological data
required to construct the primary study outcomes of link-
age and retention and other variables of interest are ex-
tracted from existing electronic patient-level databases.
Data are also used to assess comparability of the study
population to the entire HIV care clinic population en-
rolled during the study period.
Site assessments
Data on the configuration of HIV services at the ten
study sites are collected at the beginning and at the end
of the study using a standardized site assessment form.
Cost data
Costs of delivering the SOC, CIS and CIS + FI are esti-
mated by measuring utilization rates and multiplying
utilization by the resource expenditure per unit utilization:
laboratories, outpatient visits, inpatient visits, patient time
and transportation costs, staff time, expenses for staff
training, durable equipment and non-durable equipment
used by staff, and rent.
Sample size and power analysis
Based on a review of the relevant literature, under the
current SOC in Mozambique we conservatively estimated
that the combined outcome of linkage within 1 month
and retention at 12 months after HIV diagnosis would be
25% (assuming 50% of participants enroll into HIV care
within 1 month of diagnosis and 50% of these are retained
in care 12 months after diagnosis). We then estimated the
minimum difference we could detect in our combined
outcome between CIS and SOC arms with 80% power
using the Power and Sample Size (Pass 8.0) software for
two independent proportions in a cluster randomization
study design and a two-sided Farrington & Manning Like-
lihood Score Test [34], and assuming five study clusters
(two sites per cluster) and 300 patients per cluster. With
these assumptions, we will have 80% power to detect as
statistically significant a relative risk of the combined out-
come of linkage and retention between CIS and SOC arms
of 1.6 (or an absolute increase in the combined outcome
of 20%) comparing the CIS to SOC arms.
To address the objective of comparing the effectiveness
of CIS + FI to CIS on the combined outcome of linkage
within 1 month of diagnosis and 12 month retention after
diagnosis, we are enrolling an additional 150 participants
in each of the five CIS sites (total of 750 additional partici-
pants in intervention arm) in cohort 3 (CIS + FI) upon
completion of enrollment of cohort 2 (CIS). Assuming
that the combined outcome of linkage within one month
of diagnosis and retention 12 months after diagnosis is
45% in the CIS arm, we will also have greater than 80%
power to detect an absolute increase of 21% in the com-
bined outcome comparing CIS + FI to CIS.
Statistical methods
1. To evaluate the effectiveness of CIS as compared to
SOC on the combined outcome of linkage to HIV
care within 1 month and retention in care at
12 months among adults testing HIV positive.
An intent-to-treat analysis will be used to compare
the combined outcome of linkage to HIV care within
1 month and retention at 12 months between
participants at sites randomized to receive the SOC
and participants at sites randomized to receive CIS.
We will use multilevel generalized linear regression
models to provide statistical estimates controlling
for cluster and matched stratum effects. Models will
include fixed effects for study condition (treatment
arm) and random effects for sites. This approach will
take into account the correlation among participants
within facilities. In addition, we will compare
patient-level and facility-level characteristics
hypothesized to influence linkage and retention after
data collection has been completed in order to assess
whether the randomization evenly distributed
important non-matched predictors of linkage and
retention between intervention and control arms.
Covariates hypothesized to influence linkage and
retention that will be analyzed include: actual
numbers of adults enrolling in HIV care at each site
during the study period, age, gender, baseline measures
of CD4 count and WHO stage at enrollment into HIV
care, and tuberculosis status at enrollment into HIV
care. Should important differences be observed
between intervention and control arms, we will
additionally conduct covariate-adjusted generalized
linear mixed models to assess the degree to which these
differences alter our measures of association.
2. To evaluate the incremental effectiveness of CIS + FI
compared to CIS on the combined outcome of rapid
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linkage to HIV care within 1 month and retention in
care at 12 months among adults newly diagnosed
with HIV.
The approach for this objective will follow the
approach outlined under objective 1 above; in this
case, the combined outcome will be compared
between participants enrolling in cohort 3 (receiving
CIS + FI) and those enrolling approximately six
months earlier in cohort 2 (receiving CIS without
FI), all within the same study arm.
3. To evaluate the effectiveness of CIS compared to SOC
and the incremental effectiveness of CIS + FI compared
to CIS in relation to: linkage to care within one month;
retention 12 months after HIV diagnosis; time from
eligibility to ART-initiation, and disease progression.
Outcomes will be compared under an “intent to treat”
scenario and, if significant differences in other
determinants of these outcomes are observed between
study cohorts at baseline, generalized multilevel mixed
models will be used to compare outcomes between
study cohorts. In addition, linkage rates and
non-retention and mortality rates 12 months after
HIV diagnosis will be compared between study arms
using Kaplan-Meier survival analytic techniques using
robust sandwich estimates to account for clustering.
Participants who are lost to follow-up will be censored
for mortality and morbidity analyses at the time of last
known visit. For the subset of participants determined
ART eligible at their site, Cox Proportional Hazards
Models will be used to compare the time from ART
eligibility to ART initiation between participants
receiving CIS + FI, CIS and SOC, censoring
participants transferring after ART eligibility but
before initiation and treating participants who die
before ART initiation as competing risks, and using
robust sandwich estimates to account for clustering.
4. To evaluate the cost-effectiveness of CIS compared
to SOC and the incremental cost-effectiveness of
CIS + FI compared to CIS.
The incremental cost-effectiveness ratio is defined as
the incremental change in costs divided by the
incremental change in effects. This study will use
cost-effectiveness to compare SOC with CIS, CIS
with CIS + FI, and SOC with CIS + FI. The incremental
cost-effectiveness of CIS compared to SOC is equal to
the cost of CIS minus the cost of SOC divided by the
effectiveness of CIS minus the effectiveness of SOC. In
discounting future benefits expected from long-term
benefits of the proposed intervention (such as
improved life expectancy), we will explore alternative
time horizons (ranging from the period of data
collection to five years, 10 years, 20 years, and lifetime),
and we will use the standard discount rate of 3% for
costs and benefits. This discount rate reflects the time
preference with regard to costs and benefits (that is, a
dollar today is worth more than an inflation-adjusted
dollar at some time in the future). The downstream
impact of CIS and CIS + FI on future costs and benefits
(e.g. the potential impact of prolonging lives) will be
included as additional costs and benefits.
5. To assess feasibility and participant acceptability of
the interventions included in CIS and CIS + FI in
enhancing linkage and retention.
To assess feasibility of CIS and CIS + FI, uptake of
interventions will be assessed by calculating the
proportion of participants reporting that they
received each intervention during the 1- and 12-
month follow-up interviews and documented within
study records as having received them. To assess
acceptability, participants are asked to identify
whether each intervention was helpful in terms of
assisting in timely linkage to care and retention after
enrollment into care, the “most useful” and “least
useful” intervention, and to identify what aspects of
each intervention were useful and not useful.
Stratified analyses will examine associations between
participant socio-demographic and clinical
characteristics and acceptability.
Ethics
The study protocol, including recruitment, consent,
and intervention materials, was approved by the In-
stitutional Review Board (IRB) at Columbia University
(FWA00002636) and by Mozambique’s National Commit-
tee for Bioethics in Health (FWA00003139) and complies
with United States Agency for International Development
(USAID) policy on human subjects research. Study staff
has been trained in good clinical practice (GCP) and
standard operating procedures (SOP). Prior to being en-
rolled in the study, all participants are required to provide
written informed consent.
Trial status
The study was launched in April 2013 at two sites in
Maputo and all sites were actively enrolling participants
for the SOC arm and CIS cohort of the intervention arm
by December 2013. The first round of the site assess-
ment was conducted in April 2014. As of July 2014, en-
rollment is complete at eight sites (four SOC sites and
four intervention sites) with a total of 1351 participants
enrolled. Enrollment of CIS + FI participants began at
two intervention sites in June 2014.
Discussion
Study findings have the potential to substantially trans-
form clinic-based approaches to linkage to and retention
in HIV care and ultimately impact patient health out-
comes and onward HIV transmission in Mozambique
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and elsewhere in SSA. Specifically, each intervention
component in the CIS has proven efficacy in HIV care
and treatment settings but information is lacking on an
easy to deliver package of services that can improve
overall performance of the HIV care continuum. We an-
ticipate that findings from our study can help to bridge
this “know-do” gap and provide evidence of the effect-
iveness of a combination intervention strategy, and its
cost-effectiveness, in a “real-life” service delivery system.
We further anticipate that evidence from this study can
be used to inform policy decisions concerning national
HIV care and treatment policy, both in Mozambique
and in other resource-limited settings.
Indeed, to ensure local relevance of study findings,
a study advisory group—comprised of representatives
from the funding agency, the Ministry of Health, the
Mozambican National Institute of Health, and Mozambican
Association of People Living with HIV—was created
prior to study launch to advise on refinement of the
study interventions, study implementation, translation
of findings into local practice, local and international
dissemination and capacity building activities. To date,
the study advisory group has met three times and nu-
merous informal consultations have been held with in-
dividual members.
Despite intimate involvement of the Ministry of Health
in the study advisory group, several factors intrinsic to
the implementation science nature of the study have
delayed recruitment of participants, including a strike
of health worker personnel, frequent electricity short-
ages, recurrent absences of HCT counselors at the
health facilities, and intermittent shortages of HIV test-
ing kits and other supplies. Additionally, low motiv-
ation of health facility staff has created challenges for
optimal delivery of the CIS interventions. Specifically,
delays in data entry of patient information in the elec-
tronic patient-level database used to follow HIV care
patients by health facility data clerks have limited the
ability of study staff to send SMS reminder for sched-
uled follow-up appointments to all participants in the
CIS arm that have linked to care. Similarly, at several
health facilities, receptionists have been reluctant to
change their usual procedures for scheduling patient
appointments in order to expedite visits for ART eli-
gible patients as per the accelerated ART protocol.
These challenges highlight the realities of providing
high quality services and changing practices and behav-
iors in a complex, under-resourced health system that is
struggling to address the HIV epidemic. Implementation
science studies, such as the one described in this paper,
are critical to identifying the gaps between evidence and
practice and identifying strategies to close these gaps in




Trial registration: Clinicaltrials.gov, NCT01930084.
Protocol
The full trial protocol can be accessed directly on the
Clinicaltrials.gov webpage with the registration number
provided above.
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